Compare Morgan Stanley (MS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Smith & Nephew plc — how do they compare? Morgan Stanley trades at $216.93 (market cap $338.22B), while Smith & Nephew plc trades at $27.96 (market cap $11.62B). The key difference: Morgan Stanley is far larger — about 29.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| MS | SNN | |
|---|---|---|
Market Cap | $338.22B | $11.62B |
Sector | Financials | Health |
52-Week High | $228.42 | $38.53 |
52-Week Low | $151.86 | $27.80 |
Dividend Yield | 2.14% | 2.86% |
Enterprise Value | — | $14.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.33, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $239.58. Revenue grew to $66.0 billion in 2025, with net income margin expanding to 25.56%, and the company has beaten EPS estimates in recent quarters. Recent news highlights its role in leading Anthropic's IPO and advancements in AI integration for wealth management.
The outlook remains positive given strong earnings momentum and strategic initiatives, though risks include volatile cash flows from operations and high leverage. Wall Street sentiment is bullish with 55.77% of analysts rating it a Buy, supporting potential upside from current levels amid broader financial sector strength.
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
